Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines - Test2 - elhamkhani - TriplyDB

Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines

Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines

http://www.wikidata.org/entity/Q33653229

about

Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA Dual neonate vaccine platform against HIV-1 and M. tuberculosis.p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2 Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.Investigation of IRES Insertion into the Genome of Recombinant MVA as a Translation Enhancer in the Context of Transcript Decapping.Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition.Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors.A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease.Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses.MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model.Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?CRISPR/Cas9-Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development.

P2860

Q21089588-84D144F9-B2BD-4948-96FF-186AEF08434D Q24276422-A2573601-1C1C-427E-A2E6-92DB27266263 Q28727937-358EE0D0-B801-4E2E-A7B2-060953B94F4A Q33908584-A974D7F0-4B6F-47BF-A2BE-3DBD2BBAD386 Q34135426-04654FC6-D139-4CC2-8282-2210AB00AFBC Q34673436-6DD27440-2823-4EBC-912F-CDE453727063 Q35641132-5B3D901E-EC15-411C-A2DA-063D4586ACA6 Q35642108-33D4E7C4-3860-4F9C-BF7D-CA338C18F433 Q36281094-ABF4BE4B-39D6-41AF-85E8-AF6A7C6BD34A Q36559845-7118F296-EDB0-4527-B348-20ADF3BF56BF Q36756865-D34F7D68-68D3-48B9-88DE-4EC242AD85B3 Q38176419-B5D808D8-463F-4217-93BF-F299C27A52C4 Q38840631-13606E7E-66BC-4FEC-ADEB-74334EEC4B6C Q39703820-563201A5-2B35-4BD7-B514-E16707A433FE Q40497816-A1E3B6DF-2D47-49CF-B1F1-CCA1C9183E28 Q43046676-C6FF3662-3E76-440E-B480-7170E7CD6026 Q45325213-4B5139A7-1C09-411E-9B5A-F49FCBD7D464 Q47549689-2B1C2A19-3E20-4FB6-A982-E001CB53E29D

P2860

Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines

http://www.wikidata.org/entity/Q33653229

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Modified H5 promoter improves ...... ically engineered MVA vaccines

@ast

Modified H5 promoter improves ...... ically engineered MVA vaccines

@en

type

label

Modified H5 promoter improves ...... ically engineered MVA vaccines

@ast

Modified H5 promoter improves ...... ically engineered MVA vaccines

@en

prefLabel

Modified H5 promoter improves ...... ically engineered MVA vaccines

@ast

Modified H5 promoter improves ...... ically engineered MVA vaccines

@en

P1433

Q33653229-06CD820D-847B-4080-B308-426D213207AB

P1476

Q33653229-21015F6B-F475-425E-99D5-A60E98F38AEB

P2093

Q33653229-4601F6BA-EDBF-4688-A667-95CAD1762D01

Q33653229-46BBD698-46BB-4E4C-959D-F5677771D4B4

Q33653229-85AA0150-CED7-4833-A1D0-0A8239B6DC50

Q33653229-8EED1FD8-E2AC-4583-8BCE-A3514FD068F5

Q33653229-C3E60E1B-A847-4BFD-9C17-088116F8653B

Q33653229-CCCDE75B-F87A-42B1-9D45-2351C4FE9267

Q33653229-D031032C-AEC3-43F5-B9C1-312554D4B77D

Q33653229-E9FC8257-C431-48A8-83D9-5980C83A5E03

P2860

Q33653229-04A2C9D5-4A14-4CE2-B8F1-7EFB4ABF7D70

Q33653229-0505CF01-65A3-49C7-A8A7-0771D86D30FB

Q33653229-0A572631-3029-4BC8-A988-EA152AFF38A6

Q33653229-18433CCD-831F-423D-A530-EECBDF9B1F01

Q33653229-1B13B8CE-C9F0-400C-BB9E-A0D1CEB56F2D

Q33653229-32C09F07-AB5B-4519-A7DA-5DB465DB3596

Q33653229-374DB9D7-CC36-4DE0-8097-247E8A28590E

Q33653229-3F8A2559-5B82-476D-8308-876D1C9A03A3

Q33653229-4B4AA4C0-D764-4FCA-A4C1-A9D455B2D1C3

Q33653229-61E64FCB-569B-4A03-AFE6-177D58A14BBC

P304

Q33653229-22DA5693-DB1C-4928-B018-454DA42767C1

P31

Q33653229-8CE32076-9BEF-4ED5-A28E-7FA337FEE19C

P356

Q33653229-E94616D7-E06A-4208-9D17-236CF96F9460

P407

Q33653229-31C9424F-4A34-477C-B639-9E021BFAD9DE

P433

Q33653229-94B791AF-73EB-48C7-ABC9-A8C88EA42F22

P478

Q33653229-897E752A-988A-4792-BFD2-0221DA876177

P50

Q33653229-84D35817-5ADD-4C58-B9C8-934775CB9FD7

Q33653229-94B7DE4A-2340-4744-9A4F-D8D2D012EBA2

P577

Q33653229-5746E270-9830-453C-8D55-A30EF94BFDC9

P5875

Q33653229-A940BCF4-1C20-4630-B9B1-52751B5D6447

P698

Q33653229-F7EB28F2-76DB-4872-9660-07F23C700322

P932

Q33653229-E6D7350F-076B-44F8-A067-0061FCD048A9

P356

J.VACCINE.2009.11.056

P1433

P1476

Modified H5 promoter improves ...... ically engineered MVA vaccines

@en

P2093

Anindya Dasgupta

http://www.w3.org/2001/XMLSchema#string

Corinna La Rosa

http://www.w3.org/2001/XMLSchema#string

Joy Martinez

http://www.w3.org/2001/XMLSchema#string

Tumul Srivastava

http://www.w3.org/2001/XMLSchema#string

Wendi Zhou

http://www.w3.org/2001/XMLSchema#string

William J Britt

http://www.w3.org/2001/XMLSchema#string

Zhongde Wang

http://www.w3.org/2001/XMLSchema#string

Zhongqui Li

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization

Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries.

An MVA vaccine overcomes tolerance to human p53 in mice and humans.

Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.

Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8

Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.

Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.

Recombinant poxviruses as mucosal vaccine vectors.

P304

1547-1557

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2009.11.056

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Ravindra K Rawal

P577

2009-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40456003

http://www.w3.org/2001/XMLSchema#string

P698

19969118

http://www.w3.org/2001/XMLSchema#string

P932

2821965

http://www.w3.org/2001/XMLSchema#string